: A 2026 study used proteome-wide MR to identify 27 circulating proteins associated with B-cell malignancy risk, pinpointing 23 potential drug targets .

For a general review of the disease itself, current medical consensus highlights several key areas:

The phrase "" most likely refers to the use of Mendelian Randomization (MR) to evaluate the validity of causal relationships and drug targets in leukemia research .

: To ensure high validity, researchers recommend using tissue-specific instrumental variables and a threshold (typically ) to exclude redundant genetic data.

In scientific contexts, "MR" stands for Mendelian Randomization, a method used to avoid common research pitfalls like confounding factors or reverse causality. Researchers use this to identify protein associations and potential therapeutic targets for malignancies, such as B-cell leukemia. Scientific Review of "MR Validity" in Leukemia